ESPE Abstracts (2015) 84 P-3-949

ESPE2015 Poster Category 3 GH & IGF (68 abstracts)

Plexiform Neurofibroma and Demielinisant Lesions in a Patient with GH Deficiency Treated with rGH

Luminita-Nicoleta Cima a, , Alice Albu b, , Simona Fica b, & Carmen Gabriela Barbu b,

aPOSDRU/159/1.5/S/141531, Victor Babes Institute, Bucharest, Romania; b‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania; cDepartment of Endocrinology, Elias Hospital, Bucharest, Romania

Case report: A 13-year old boy treated with rGH for short stature due to isolated GH deficiency was submitted in our clinic in June 2014 for regular follow-up. From his medical history we note that he was diagnosed with GH deficiency in 2009 (−4.5 S.D.) and started treatment with rGH 0.035 mg/kgc per day since February 2009. The physical exam showed H=149.9 cm (−0.74 S.D.), 39 kg, Tanner P3G3 and a subcutaneous left paravertebral tumour in the toracal region reported to be painful by the patient. The tumour had hard consistency, was mobile and had no sign of inflammation. A spinal MRI was performed that showed a left paramedian toracal tumour located from T7 to T9 with extension in the left VIIIth foramen that raised the suspicion for a toracal neurofibroma with intra and extraforamen extension. He was sent to surgery and the biopsy revealed a plexiform neurofibroma. In October 2014 (4 months later), a spinal MRI was performed that showed no signs of restant tumour or relapse. Taking into account the patient’s family complaint of child’s poor scholar performance and memory loss, a cerebral MRI was done revealing some demielinisant supratentorial lesions; consequently, the patient is currently under evaluation in the paediatric neurology department.

Particularity: In this case, a keypoint resides in the fact that the tumour was discovered early due to the periodic follow-up for GH therapy but another issue might be the continuance of the GH-therapy.

Funding: This paper is partly supported by the Sectorial Operational Programme Human Resources Development (SOPHRD), financed by the European Social Fund and the Romanian Government under the contract number POSDRU 141531.

Article tools

My recent searches

No recent searches.